Articles, insights, and posts about Child Development, early detection, and new methods in diagnosis and treatment.
In April 2017, FDNA analyzed patient data from syndromes categorized as Overgrowth Syndromes as part of the Year of Discovery, in partnership with Invitae and Child Growth Foundation. A research team at FDNA, dedicated to making new discoveries with this data, has released new results, in addition to the March RASopathy findings, in the ongoing […]
In March, FDNA reached out to clinicians and patients globally as part of the Year of Discovery to collect and analyze patient data from a category of syndromes known as RASopathies, in partnership with Blueprint Genetics and the Noonan Syndrome Foundation. A research team at FDNA, dedicated to making new discoveries with this data, has released […]
published as part of Access A.I.’s publication: “AI and Business: a Practical Guide.“ Our world is filled with data. Data on your shopping habits. Data on your physical health. Data on your genetics. The challenge of gaining insights lies not in a lack of data, but in a lack of using that data in a […]
Dekel Gelbman, CEO of FDNA, was featured in Health Data Management discussing the value for hospitals of using clinical data warehouses for the storage and analysis of genomic and phenotypic information. Below is an excerpt: There are more than 7,000 rare diseases for physicians to consider when diagnosing a patient. For even the most experienced […]
FDNA’s Year of Discovery Initiative will spotlight a different genetic syndrome group each month as part of their mission to accelerate advancements and discoveries for all rare diseases. Boston, MA. March 9, 2017— FDNA launched the Year of Discovery on February 28th, 2017 to unite clinicians, labs and patients for rare disease advancements. March, the […]
Dekel Gelbman, CEO of FDNA, was featured in the Medical Device and Diagnostics Industry, discussing the value of facial analysis technology and phenotyping in discovering rare disease diagnoses. Below is an excerpt: Diagnosing rare and ultra-rare genetic diseases can be extremely difficult for geneticists. The diagnostic odyssey, from the primary point of care, through the […]
Dekel Gelbman, CEO of FDNA, was featured in Becker’s Hospital Review, discussing the value of phenotyping to hospitals involved in rare disease workflows. Below is an excerpt: Diagnosing rare diseases is like solving a puzzle, with physicians trying to fit together many complex clues. Unfortunately, the 10% of the population who suffer from a rare […]
Boston-based health and tech start-up calls on patients and clinicians to share their stories to help make new discoveries needed to diagnose and treat rare genetic diseases February 28, 2017 09:00 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Today, FDNA announces the launch of its Year of Discovery initiative. Beginning in March, the Year of Discovery initiative […]